References
- 1. Klára G, Zsuzsanna F. A farmakológia alapjai. Medicina; 2011 p. 216-225.
- 2. Beale JM, Block JH, editors. Wilson and Gisvold’s Textbook of organic medicinal and pharmaceutical chemistry. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011 p 811-818.
- 3. Shepherd AJ, Joly-Mascheroni RM. Visual motion processing in migraine: enhanced motion after-effects are related to display contrast, visual symptoms, visual triggers and attack frequency. Cephalalgia. 2017 Apr;37(4):315-26.
- 4. Tabet P, Saliba I. Meniere’s disease and vestibular migraine: updates and review of the literature. J Clin Med Res. 2017 Sep;9(9):733–744.
- 5. Shah DR, Dilwali S, Friedman DI. Current Aura Without Headache. Curr Pain Headache Rep. 2018 Nov 1;22(11):77.
- 6. Vgontzas A, Burch R. Episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks. Curr Pain Headache Rep. 2018 Dec 1;22(12):78.
- 7. Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B et al. Male and female sex hormones in primary headaches. The journal of headache and pain. 2018 Dec;19(1):117.
- 8. Dalmau LG, Navarro EG, Cuella EC, Santafe M. Factores dietéticos involucrados en la migraña aguda. Revisión sistemática. Rev Esp Nutr Comunitaria. 2018;24(1).
- 9. Csépány, É., et al. Current pharmacotherapy in migraine. Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesület lapja. 2015, 17.4: 169-176.
- 10. Ramadan NM, Buchanan TM. New and future migraine therapy. Pharmacology & therapeutics. 2006 Oct;112(1):199-212.
- 11. Tajti J, Szok D, Csáti A, Vécsei L. Prophylactic drug treatment of migraine in children and adolescents: an update. Curr Pain Headache Rep. 2016 Jan;20(1):1.
- 12. Bohm PE, Stancampiano FF, Rozen TD. Migraine Headache: Updates and Future Developments. Mayo Clinic Proceedings 2018 Nov;93(11):1648-1653
- 13. Schwedt TJ. Preventive Therapy of Migraine. Continuum (Minneap Minn). 2018 Aug;24(4):1052-65.
- 14. Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol. 2019 Mar 4;15(3):189-98.
- 15. Munksgaard SB, Madsen SK, Wienecke T. Treatment of Medication Overuse Headache–a review. Acta Neurol Scand. 2019 May;139(5):405-414.
- 16. Waldman SD. Atlas of Common Pain Syndromes E-Book. Elsevier Health Sciences; 2018.
- 17. Cargnin S, Viana M, Sances G, Cantello R, Tassorelli C, Terrazzino S. Using a Genetic Risk Score Approach to Predict Headache Response to Triptans in Migraine Without Aura. Int J Clin Pharmacol Ther. 2019 Feb;59(2):288-94.
- 18. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology. 1989 Sep;39(9):1239-.
- 19. Macone AE, Perloff MD. Triptans and migraine: advances in use, administration, formulation, and development. Expert opinion on pharmacotherapy. 2017 Mar;18(4):387-97.
- 20. Soldin OP, Dahlin J, O’Mara DM. Triptans in pregnancy. Therapeutic drug monitoring. 2008 Feb;30(1):5.
- 21. Humphrey PP. The discovery and development of the triptans, a major therapeutic breakthrough. Headache: The Journal of Head and Face Pain. 2008 May;48(5):685-7.
- 22. Chadha N, Silakari O. Indoles: As Multitarget Directed Ligands in Medicinal Chemistry. In: Silakari O editor. Key Heterocycle Cores for Designing Multitargeting Molecules Silakari. Amsterdam: Elsevier. 2018. p. 285-321.
- 23. ***European Pharmacopoeia 9th Edition, European Department for the Quality of Medicines within the Council of Europe, Strasbourg, 2016.
- 24. ***The United States Pharmacopoeia 37-National Formulary 32, Rockville, 2014
- 25. https://www.ema.europa.eu/en (Megtekintés dátuma: 2019.05.13.)
- 26. https://www.anm.ro/nomenclator/medicamente (Megtekintés dátuma: 2019.05.13.)
- 27. DOS 3 320 521 (Glaxo; appl. 6.7.1983; GB-prior. 7.6.1982).
- 28. Velickova N. Drugs like risks factors for oral-facial clefts. Macedonian Pharmaceutical Bulletin, 2011(57):147-8.
- 29. Komsta L, Waksmundzka-Hajnos M, Sherma J, editors. Thin layer chromatography in drug analysis. Taylor & Francis; 2014, 344.
- 30. El-Bagary RI, Mohammed NG, Nasr HA. Two chromatographic methods for the determination of some antimigraine drugs. Anal Chem Insights. 2012 jan;7:13-21.
- 31. Srinivasu MK, Rao BM, Sridhar G, Kumar PR, Chandrasekhar KB, Islam A. A validated chiral LC method for the determination of zolmitriptan and its potential impurities, J Pharm Biomed Anal. 2005 Mar;37(3):453-60.
- 32. Rezk MR, Michael AM, Lotfy HM, El-Kadi AO, Shehata MA. A rapid and sensitive HPLC assay of some concomitant anti-migraine drugs. J Chromatogr Sci. 2013 Jul;52(7):704-6.
- 33. Rao BM, Srinivasu MK, Sridhar G, Kumar PR, Chandrasekhar KB, Islam A. A stability indicating LC method for zolmitriptan. J pharmaceutl biomed. 2005 Sep;39(3-4):503-9.
- 34. Ahmed S, Atia NN. Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. J pharmaceutl biomed. 2017 Sep;143:241-51.
- 35. Saka C. Review of analytical methods for identification and determination of triptans. Critical Reviews in Analytical Chemistry. 2009 Feb 3;39(1):32-42.
- 36. Ferrari MD, Saxena PR. 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol. 1995 Mar;2(1):5-21.
- 37. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016 May;5:637.
- 38. Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. The American Journal of Medicine Supplements. 2005 Mar;118:36-44.
- 39. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010 Aug;70(12):1505-18.
- 40. Aurélia U, János T, László V. A migrénes roham kezelése trip-tánokkal. Lege Artis Medicinae. 2004 Mar;14(3):191-7.
- 41. Mathew NT, Loder EW. Evaluating the triptans. The American Journal of Medicine Supplements. 2005 Mar;118:28-35.
- 42. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003 Mar;2(2):123-32.
- 43. Evans DC, O’Connor D, Lake BG, Evers R, Allen C, Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
- 44. Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS drugs. 2012 Sep;26(9):791-811.
- 45. Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S. Frovatriptan: a review of drug-drug interactions. J Headache Pain. 2002 Apr;42:63-73.
- 46. Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia. 2004 Jun;24(6):417-24.
- 47. Meiyanti M. The role of triptans in the management of migraine. Universa Medicina. 2016 Feb;28(1):49-58.
- 48. Ostroff JL, Ostroff ML. An Overview of Generic Triptans for Migraine. US Pharm. 2017;42(6):14-8.
- 49. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003 Mar;2(2):123-32.
- 50. Mathew NT, Loder EW. Evaluating the triptans. The American Journal of Medicine Supplements. 2005 Mar;118:28-35.
- 51. Buzzi MG. Triptan efficacy in migraine attacks: from appropriate diagnosis to metabolic profiles and pharmacogenomics. Drug Dev Res. 2007 Sep;68(6):335-40.
- 52. Roberto G, Piccinni C, D’Alessandro R, Poluzzi E. Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database. Cephalalgia. 2014 Jan;34(1):5-13.
- 53. Tepper SJ. Safety and rational use of the triptans. Medical Clinics of North America. 2001 Jul;85(4):959-70.
- 54. https://www.fda.gov/ (Megtekintés dátuma: 2019.05.13.)
- 55. Chaplin S, MacGregor A. Triptans: properties and use in the treatment of acute migraine. Prescriber. 2012 Sep 5;23(17):45-8.
- 56. Tajti J, Majláth Z, Szok D, Csáti A, Vécsei L. Drug safety in acute migraine treatment. Expert Opin Drug Saf. 2015 Jun;14(6):891-909.
- 57. Silberstein SD, Marcus DA. Sumatriptan: treatment across the full spectrum of migraine. Expert opinion on pharmacotherapy. 2013 Aug;14(12):1659-67.
- 58. Lionetto L, Casolla B, Mastropietri F, D’Alonzo L, Negro A, Simmaco M et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):1043-50.
- 59. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Zolmitriptan (Zomig). Expert Rev Neurother. 2004 Jan;4(1):33-41.
- 60. Stark RJ, Stark CD. Migraine prophylaxis. Med J Aust. 2008 Sep;189(5):283-8.
- 61. Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia. 2000 Nov;20(Suppl 1):2-9.
- 62. Cady RK, Farmer K. Managing migraine by patient profile: role of frovatriptan. Patient Prefer Adherence. 2016 Apr;10:5019510.
- 63. Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, Martelletti P. Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab Toxicol. 2011 Nov 1;7(11):1449-58.
- 64. Negro A, Lionetto L, D’Alonzo L, Casolla B, Marsibilio F, Vignaroli G, et al. Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2013 May;9(5):637-44.
- 65. Gras J, Llenas J, Jansat JM, Jáuregui J, Cabarrocas X, Palacios JM. Almotriptan, a new anti-migraine agent: A review. CNS drug reviews. 2002 Sep;8(3):217-34.
- 66. Sandrini G, Perrotta A, Nappi G. Eletriptan: a review and new perspectives. Expert Rev Neurother. 2006 Oct 1;6(10):1413-21.
- 67. Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A et al. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Therapeutic advances in neurological disorders. 2016 Sep;9(5):414-23.
- 68. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021926s000TOC.cfm (Megtekintés dátuma: 2019.05.13.)